See more : Wai Chun Group Holdings Limited (1013.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Avid Bioservices, Inc. (CDMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avid Bioservices, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Dev Information Technology Limited (DEVIT.NS) Income Statement Analysis – Financial Results
- Nidec Corporation (NJDCY) Income Statement Analysis – Financial Results
- Lakeland Bancorp, Inc. (LBAI) Income Statement Analysis – Financial Results
- Khiron Life Sciences Corp. (KHRWF) Income Statement Analysis – Financial Results
- Odin Metals Limited (ODM.AX) Income Statement Analysis – Financial Results
Avid Bioservices, Inc. (CDMO)
About Avid Bioservices, Inc.
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 139.91M | 149.27M | 119.60M | 95.87M | 59.70M | 53.60M | 53.62M | 57.63M | 44.69M | 26.78M | 22.40M | 21.68M | 15.23M | 13.49M | 27.94M | 18.15M | 6.09M | 3.71M | 3.19M | 4.96M | 3.31M | 3.92M | 3.77M | 979.00K | 1.00K | 100.00K | 500.00K | 300.00K | 3.10M | 100.00K |
| Cost of Revenue | 132.59M | 117.79M | 82.95M | 66.56M | 55.77M | 46.38M | 56.55M | 38.26M | 22.97M | 15.59M | 13.11M | 12.60M | 10.15M | 7.30M | 8.72M | 9.06M | 4.80M | 3.30M | 3.30M | 4.40M | 2.21M | 2.86M | 0.00 | -412.00K | -516.00K | 3.50M | -700.00K | -300.00K | 0.00 | 1.00M |
| Gross Profit | 7.32M | 31.48M | 36.65M | 29.31M | 3.93M | 7.22M | -2.92M | 19.37M | 21.72M | 11.19M | 9.29M | 9.09M | 5.08M | 6.20M | 19.23M | 9.09M | 1.29M | 412.00K | -104.00K | 558.00K | 1.10M | 1.06M | 3.77M | 1.39M | 517.00K | -3.40M | 1.20M | 600.00K | 3.10M | -900.00K |
| Gross Profit Ratio | 5.23% | 21.09% | 30.64% | 30.57% | 6.59% | 13.48% | -5.45% | 33.61% | 48.61% | 41.78% | 41.48% | 41.91% | 33.35% | 45.92% | 68.81% | 50.06% | 21.16% | 11.11% | -3.26% | 11.25% | 33.25% | 27.06% | 100.00% | 142.08% | 51,700.00% | -3,400.00% | 240.00% | 200.00% | 100.00% | -900.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.30M | 59.53M | 43.00M | 27.72M | 24.31M | 35.69M | 29.46M | 24.66M | 18.42M | 18.28M | 15.88M | 12.42M | 11.16M | 9.67M | 8.74M | 13.51M | 7.38M | 8.08M | 8.80M | 7.60M | 30.00M | 1.70M | 0.00 |
| General & Administrative | 25.20M | 27.18M | 20.63M | 16.76M | 14.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.48M | 3.81M | 4.24M | 6.20M | 4.50M | 3.30M | 900.00K | 700.00K |
| Selling & Marketing | 800.00K | 700.00K | 600.00K | 300.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.00M | 27.88M | 21.23M | 17.06M | 14.52M | 12.85M | 16.46M | 19.33M | 18.55M | 18.69M | 17.27M | 13.13M | 11.46M | 11.42M | 8.18M | 6.98M | 7.15M | 6.45M | 6.56M | 5.10M | 4.23M | 2.99M | 2.48M | 3.81M | 4.24M | 6.20M | 4.50M | 3.30M | 900.00K | 700.00K |
| Other Expenses | 1.00 | 1.00M | -81.00K | 133.00K | 355.00K | 0.00 | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 412.00K | 516.00K | 1.00M | 700.00K | 300.00K | 200.00K | 200.00K |
| Operating Expenses | 26.00M | 27.88M | 21.23M | 17.06M | 14.52M | 12.85M | 16.46M | 47.63M | 78.08M | 61.69M | 45.00M | 37.44M | 47.15M | 40.88M | 32.84M | 25.40M | 25.43M | 22.32M | 18.98M | 16.26M | 13.90M | 11.73M | 15.98M | 11.60M | 12.83M | 16.00M | 12.80M | 33.60M | 2.80M | 900.00K |
| Cost & Expenses | 158.59M | 145.67M | 104.18M | 83.63M | 70.29M | 59.23M | 73.00M | 85.89M | 101.05M | 77.28M | 58.11M | 50.04M | 57.30M | 48.18M | 41.56M | 34.47M | 30.23M | 25.62M | 22.28M | 20.66M | 16.11M | 14.59M | 15.98M | 11.19M | 12.31M | 19.50M | 12.10M | 33.30M | 2.80M | 1.90M |
| Interest Income | 0.00 | 2.60M | 2.68M | 133.00K | 474.00K | 282.00K | 102.00K | 108.00K | 722.00K | 142.00K | 349.00K | 322.00K | 41.00K | 1.05M | 116.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.34M | 2.60M | 2.68M | 1.16M | 8.00K | 11.00K | 27.00K | 7.00K | 14.00K | 1.00K | 5.00K | 54.00K | 90.00K | 516.00K | 997.00K | 408.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 11.11M | 7.21M | 4.48M | 3.45M | 3.09M | 2.75M | 2.56M | 2.46M | 1.54M | 1.04M | 986.00K | 1.09M | 908.00K | 652.00K | 1.12M | 503.00K | 486.00K | 866.00K | 415.00K | 325.00K | 2.19M | 1.38M | 424.00K | 412.00K | 516.00K | 1.00M | 700.00K | 300.00K | 200.00K | 200.00K |
| EBITDA | -11.48M | 10.91M | 19.90M | 15.70M | -7.38M | -2.59M | -16.82M | 3.76M | 5.02M | -49.32M | -34.37M | -28.64M | -41.12M | -32.98M | -13.05M | -15.61M | -23.65M | -21.04M | -18.67M | -15.38M | -10.61M | -9.29M | -11.79M | -9.80M | -11.79M | -18.50M | -11.30M | -32.90M | 500.00K | -1.60M |
| EBITDA Ratio | -8.21% | 3.08% | 12.83% | 12.91% | -17.14% | -10.49% | -35.95% | -48.85% | -121.07% | -184.15% | -153.44% | -129.27% | -276.18% | -257.09% | -44.72% | -87.12% | -388.22% | -567.53% | -623.14% | -310.12% | -320.19% | -236.90% | -313.17% | -1,000.20% | -960,400.00% | -18,800.00% | -2,180.00% | -10,900.00% | 22.58% | 3,400.00% |
| Operating Income | -18.68M | -2.61M | 10.86M | 8.92M | -10.59M | -5.62M | -20.64M | -28.26M | -56.36M | -50.50M | -35.71M | -28.35M | -42.07M | -34.69M | -13.61M | -16.32M | -24.14M | -21.91M | -19.08M | -15.70M | -12.80M | -10.67M | -12.22M | -10.21M | -12.31M | -19.40M | -11.60M | -33.00M | 300.00K | -1.80M |
| Operating Income Ratio | -13.35% | -1.75% | 9.08% | 9.31% | -17.73% | -10.49% | -38.49% | -49.04% | -126.12% | -188.56% | -159.39% | -130.76% | -276.18% | -257.09% | -48.72% | -89.89% | -396.19% | -590.88% | -597.65% | -316.68% | -386.12% | -272.12% | -324.43% | -1,043.21% | -1,231,000.00% | -19,400.00% | -2,320.00% | -11,000.00% | 9.68% | -1,800.00% |
| Total Other Income/Expenses | -8.25M | -2.01M | -2.76M | -1.03M | 119.00K | 282.00K | 75.00K | 101.00K | 708.00K | 141.00K | 344.00K | -1.43M | -49.00K | 536.00K | 13.61M | 16.32M | 964.00K | 1.11M | 2.02M | 252.00K | -1.55M | 0.00 | 0.00 | -9.00K | -2.19M | 499.00K | 0.00 | 0.00 | -200.00K | -5.00M |
| Income Before Tax | -26.93M | 2.00M | 12.66M | 11.21M | -10.47M | -5.34M | -20.56M | -28.16M | -55.65M | -50.36M | -35.36M | -29.78M | -34,151.00B | -34,151.00B | -14,494.00B | -16,524.00B | 0.00 | 0.00 | -17.85M | 0.00 | -14.35M | 0.00 | 0.00 | -10.22M | -14.50M | -19.00M | 0.00 | 0.00 | 100.00K | -6.80M |
| Income Before Tax Ratio | -19.25% | 1.34% | 10.59% | 11.70% | -17.53% | -9.96% | -38.35% | -48.86% | -124.54% | -188.04% | -157.86% | -137.34% | -224,190,901.33% | -253,120,367.63% | -51,869,877.97% | -91,036,306.54% | 0.00% | 0.00% | -559.16% | 0.00% | -432.86% | 0.00% | 0.00% | -1,044.13% | -1,450,000.00% | -19,000.00% | 0.00% | 0.00% | 3.23% | -6,800.00% |
| Income Tax Expense | 113.83M | 1.44M | -115.01M | -2.29M | -3.21M | -284.00K | -1.29M | -2.36M | 722.00K | 142.00K | 349.00K | -1.03M | 536.00B | 536.00B | -881.00B | -208.00B | -964.00K | -1.11M | -2.02M | -252.00K | 0.00 | 889.00K | -500.00K | -678.00K | 2.20M | 100.00K | 200.00K | 200.00K | 0.00 | 5.10M |
| Net Income | -140.75M | 560.00K | 127.67M | 11.21M | -7.26M | -4.22M | -21.81M | -28.16M | -55.65M | -50.36M | -35.36M | -29.78M | -42.12M | -34.15M | -14.49M | -16.52M | -23.18M | -20.80M | -17.06M | -15.45M | -14.35M | -11.56M | -11.72M | -9.54M | -14.51M | -19.50M | -11.80M | -33.20M | 300.00K | -6.90M |
| Net Income Ratio | -100.60% | 0.38% | 106.75% | 11.70% | -12.15% | -7.86% | -40.68% | -48.86% | -124.54% | -188.04% | -157.86% | -137.34% | -276.50% | -253.12% | -51.87% | -91.04% | -380.37% | -560.84% | -534.33% | -311.60% | -432.86% | -294.80% | -311.15% | -973.95% | -1,451,400.00% | -19,500.00% | -2,360.00% | -11,066.67% | 9.68% | -6,900.00% |
| EPS | -2.23 | 0.01 | 2.08 | 0.06 | -0.13 | -0.08 | -0.46 | -0.76 | -1.80 | -1.93 | -1.53 | -1.73 | -3.53 | -3.93 | -2.07 | -2.56 | -3.67 | -3.79 | -3.55 | -3.73 | -3.74 | -3.47 | -3.92 | -3.51 | -6.26 | -10.32 | -13.35 | -54.25 | 0.70 | -15.40 |
| EPS Diluted | -2.23 | 0.01 | 1.81 | 0.06 | -0.13 | -0.08 | -0.46 | -0.76 | -1.80 | -1.93 | -1.53 | -1.73 | -3.53 | -3.93 | -2.07 | -2.56 | -3.67 | -3.79 | -3.55 | -3.73 | -3.74 | -3.47 | -3.92 | -3.51 | -6.26 | -10.32 | -13.35 | -54.25 | 0.70 | -15.40 |
| Weighted Avg Shares Out | 63.20M | 62.27M | 61.48M | 58.22M | 56.33M | 55.98M | 47.06M | 37.11M | 30.90M | 26.08M | 23.08M | 17.20M | 11.94M | 8.70M | 7.01M | 6.46M | 6.32M | 5.49M | 4.81M | 4.14M | 3.84M | 3.33M | 2.99M | 2.72M | 2.32M | 1.89M | 884.22K | 611.98K | 428.57K | 448.05K |
| Weighted Avg Shares Out (Dil) | 63.20M | 63.78M | 70.47M | 59.43M | 56.33M | 55.98M | 47.06M | 37.11M | 30.90M | 26.08M | 23.08M | 17.20M | 11.94M | 8.70M | 7.01M | 6.46M | 6.32M | 5.49M | 4.81M | 4.14M | 3.84M | 3.33M | 2.99M | 2.72M | 2.32M | 1.89M | 884.22K | 611.98K | 428.57K | 448.05K |
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Avid Bioservices, Inc.
NEW YORK , Nov. 7, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Avid Bioservices, Inc. (NASDAQ: CDMO) and its board of directors concerning the proposed acquisition of the company by GHO Capital Partners LLP...
CDMO Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Avid Bioservices to GHO Capital Partners and Ampersand Capital Partners
MONSEY, New York, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Avid Bioservices (Nasdaq: CDMO) (“Avid”) to GHO Capital Partners (“GHO”) and Ampersand Capital Partners...
Avid Bioservices to be acquired by GHO and Ampersand for about $1.1 bln
Avid Bioservices said on Wednesday that it has agreed to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in a deal valued at about $1.1 billion.
Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction
TUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development...
Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024
JERUSALEM , Oct. 31, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices unit, today announced that it will be showcasing its innovative I&I...
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference
TUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today...
Avid Bioservices, Inc. (CDMO) Q1 2025 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ:CDMO ) Q1 2025 Earnings Conference Call September 9, 2024 4:30 PM ET Company Participants Tim Brons - IR, Vida Strategic Partners Nick Green - President and CEO Dan Hart - CFO Matt Kwietniak - Chief Commercial...
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
-- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million --
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024
TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it...
Source: https://incomestatements.info
Category: Stock Reports